Charles River Laboratories International, Inc. is a prominent non-clinical contract research organization that offers a range of services, including drug discovery, non-clinical development, and safety testing across various global markets, including the United States, Europe, Canada, and the Asia Pacific. The cost of revenue for the company is $2,789,809,000.00 showcasing its production and operational expenses that support its comprehensive service offerings. With an operating income ratio of 0.13 the company's operational profitability margin reflects its ability to maintain efficiency in its business activities. Additionally, the company incurred an interest expense of $107,029,000.00 which indicates its debt servicing obligations and financial commitments. The total costs and expenses for the company amount to $3,507,543,000.00 reflecting its overall spending in pursuit of excellence in research services. Furthermore, the gross profit ratio is 0.31 which assesses the efficiency of the company's production and sales operations, underscoring its strategic management practices and financial health. Moving forward, the stock is reasonably priced at $155.39 appealing to a broad range of investors seeking opportunities in the market. The stock has an average trading volume of 937,032.00 indicating moderate liquidity, which is favorable for both institutional and retail investors. With a mid-range market capitalization of $7,835,096,648.00 the company is recognized as a steady performer within the competitive landscape. It is a key player in the Medical - Diagnostics & Research industry, contributing significantly to the overall market landscape through its innovative approaches and extensive portfolio of services. Moreover, it belongs to the Healthcare sector, driving innovation and growth that enhance its reputation and stability in the industry as it responds to evolving market needs.